Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLCG1 | P19174 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | CFTR | P13569 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8834494 | 0.85 | TDP1 (0.53) | PLCG1TDP1MAP2K1KDM4EL3MBTL1 | |
| SCHEMBL2800784 | 0.83 | TSHR (0.54) | PLCG1KDM4EL3MBTL1ALDH1A1HSD17B10 | |
| SCHEMBL2961058 | 0.81 | PLCG1 (0.49) | PLCG1TDP1KDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL6543887 | 0.80 | BDKRB1 (0.48) | PLCG1KDM4EALDH1A1POLBCNR2 | |
| SCHEMBL1663588 | 0.79 | KDM4E (0.57) | PLCG1TDP1KDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL13041790 | 0.79 | PLCG1 (0.44) | PLCG1MAP2K1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL10568384 | 0.78 | NLRP3 (0.48) | ALDH1A1POLBATMLMNATSHR | |
| SCHEMBL1972332 | 0.78 | ATR (0.44) | PLCG1TDP1MAP2K1KDM4EALDH1A1 | |
| SCHEMBL10402120 | 0.77 | KDM4E (0.55) | PLCG1TDP1KDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL9596105 | 0.77 | PARP1 (0.56) | PLCG1TDP1KDM4EL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479858-B2 | Macrocyclic compounds as sting agonists and methods and uses thereof | LUPIN LIMITED (IN) | 2025-11-25 | — | — | US | disclosed |
| EP-4004002-B1 | MACROCYCLIC COMPOUNDS AS STING AGONISTS AND METHODS AND USES THEREOF | LUPIN LTD (IN) | 2024-07-10 | — | — | EP | disclosed |
| CN-114174303-B | Macrocyclic compounds as STING agonists and methods and uses thereof | 印度鲁宾有限公司 | 2024-06-25 | — | — | CN | disclosed |
| EP-3077008-B1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | HAN JIE (CN) | 2023-10-04 | — | — | EP | disclosed |
| US-20220289763-A1 | Macrocyclic Compounds as Sting Agonists and Methods and Uses Thereof | LUPIN LIMITED (IN) | 2022-09-15 | — | — | US | disclosed |
| EP-4004002-A1 | MACROCYCLIC COMPOUNDS AS STING AGONISTS AND METHODS AND USES THEREOF | Lupin Limited (IN) | 2022-06-01 | — | — | EP | disclosed |
| CN-114174303-A | Macrocyclic compounds as STING agonists, methods and uses thereof | 印度鲁宾有限公司 | 2022-03-11 | — | — | CN | disclosed |
| WO-2021014365-A1 | MACROCYCLIC COMPOUNDS AS STING AGONISTS AND METHODS AND USES THEREOF | LUPIN LIMITED (IN) | 2021-01-28 | — | — | WO | disclosed |
| US-20200291086-A1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | Han, Jie (US) | 2020-09-17 | — | — | US | disclosed |
| US-10626156-B2 | Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs | Han, Jie (US) | 2020-04-21 | — | — | US | disclosed |
| US-20060106218-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2006-05-18 | — | — | US | disclosed |
| EP-1423120-A4 | 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF | ICOS CORP (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20050256130-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2005-11-17 | — | — | US | disclosed |
| US-6924284-B2 | PARP inhibitors | ICOS CORPORATION (US) | 2005-08-02 | — | — | US | disclosed |
| WO-2005056015-A1 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX, INC. (US) | 2005-06-23 | — | — | WO | disclosed |
| EP-1423120-A1 | 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF | ICOS CORPORATION (US) | 2004-06-02 | — | — | EP | disclosed |
| US-20040087588-A1 | Parp inhibitors | ICOS CORPORATION | 2004-05-06 | — | — | US | disclosed |
| WO-2003015785-A1 | 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF | ICOS CORPORATION (US) | 2003-02-27 | — | — | WO | disclosed |
| US-4908375-A | Fungicides | RHONE-POULENC AGROCHIMIE (FR) | 1990-03-13 | — | — | US | disclosed |
| US-4851396-A | Fungicidal compositions based on nicotinic acid derivatives, new nicotinic acid derivatives and preparation thereof | RHONE-POULENC AGROCHIMIE (FR) | 1989-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479858-B2 | Macrocyclic compounds as sting agonists and methods and uses thereof | STING1, CGAS, MAVS | PLCG1 777/4885TDP1 251/4885MAP2K1 4712/4885 |
| US-20040087588-A1 | Parp inhibitors | PARP1, PARP2, PARP11 | PLCG1 1708/4885TDP1 30/4885MAP2K1 1471/4885 |
| US-10626156-B2 | Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs | NOS2, EGLN2, HPGD | PLCG1 4235/4885TDP1 1341/4885MAP2K1 4847/4885 |
| US-20060106218-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | PLCG1 3622/4885TDP1 3835/4885MAP2K1 3068/4885 |
| US-20050256130-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | PLCG1 3622/4885TDP1 3835/4885MAP2K1 3068/4885 |
| US-20220289763-A1 | Macrocyclic Compounds as Sting Agonists and Methods and Uses Thereof | STING1, CGAS, MAVS | PLCG1 777/4885TDP1 251/4885MAP2K1 4712/4885 |
| US-20200291086-A1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | NOS2, EGLN2, HPGD | PLCG1 4235/4885TDP1 1341/4885MAP2K1 4847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.